Investors & Media

Investors & Media

Corporate Profile

Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI diseases. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related diseases. We plan to initiate Phase 3 clinical trials for the treatment of erosive GERD and the treatment of H. pylori infection. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years.

Phathom has assembled a team of seasoned gastrointestinal and pharmaceutical industry experts with deep expertise in developing GI therapeutics, including anti-secretory agents.

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

January 6, 2020
Martin Gilligan joins from Celgene Corporation where he led marketing, market access and business development for the Inflammation & Immunology Franchise FLORHAM PARK, N.J. --(BUSINESS WIRE)--Jan. 6, 2020-- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical...
December 23, 2019
BUFFALO GROVE, Ill. --(BUSINESS WIRE)--Dec. 23, 2019-- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the initiation of PHALCON-HP....
December 2, 2019
BUFFALO GROVE, Ill. --(BUSINESS WIRE)--Dec. 2, 2019-- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the initiation of PHALCON-EE, the Company’s...

Latest Events

Nov 20, 2019 at 10:40 AM GMT